Next Article in Journal
Synthesis and Antimicrobial Activity of 6-Thioxo-6,7-dihydro-2H-[1,2,4]triazino[2,3-c]-quinazolin-2-one Derivatives
Previous Article in Journal
Corrigendum to "Inhibition of Key Digestive Enzymes Related to Diabetes and Hyperlipidemia and Protection of Liver-Kidney Functions by Trigonelline in Diabetic Rats" [Sci Pharm. 2013; 81: 233–246]
 
 
Scientia Pharmaceutica is published by MDPI from Volume 84 Issue 3 (2016). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Austrian Pharmaceutical Society (Österreichische Pharmazeutische Gesellschaft, ÖPhG).
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Selective Phosphodiesterase 4B Inhibitors: A Review

by
Mohammed Afzal AZAM
* and
Naga Srinivas TRIPURANENI
Department of Pharmaceutical Chemistry, J. S. S. College of Pharmacy, Ootacamund-643001, Tamil Nadu, India
*
Author to whom correspondence should be addressed.
Sci. Pharm. 2014, 82(3), 453-482; https://doi.org/10.3797/scipharm.1404-08
Submission received: 19 April 2014 / Accepted: 10 June 2014 / Published: 10 June 2014

Abstract

Phosphodiesterase 4B (PDE4B) is a member of the phosphodiesterase family of proteins that plays a critical role in regulating intracellular levels of cyclic adenosine monophosphate (cAMP) by controlling its rate of degradation. It has been demonstrated that this isoform is involved in the orchestra of events which includes inflammation, schizophrenia, cancers, chronic obstructive pulmonary disease, contractility of the myocardium, and psoriatic arthritis. Phospho-diesterase 4B has constituted an interesting target for drug development. In recent years, a number of PDE4B inhibitors have been developed for their use as therapeutic agents. In this review, an up-to-date status of the inhibitors investigated for the inhibition of PDE4B has been given so that this rich source of structural information of presently known PDE4B inhibitors could be helpful in generating a selective and potent inhibitor of PDE4B.
Keywords: Phosphodiesterases (PDE) enzymes; Cyclic adenosine monophosphate; Selective PDE inhibitors; Chronic obstructive pulmonary disease; Antiproliferative activity; PDE4B Phosphodiesterases (PDE) enzymes; Cyclic adenosine monophosphate; Selective PDE inhibitors; Chronic obstructive pulmonary disease; Antiproliferative activity; PDE4B

Share and Cite

MDPI and ACS Style

AZAM, M.A.; TRIPURANENI, N.S. Selective Phosphodiesterase 4B Inhibitors: A Review. Sci. Pharm. 2014, 82, 453-482. https://doi.org/10.3797/scipharm.1404-08

AMA Style

AZAM MA, TRIPURANENI NS. Selective Phosphodiesterase 4B Inhibitors: A Review. Scientia Pharmaceutica. 2014; 82(3):453-482. https://doi.org/10.3797/scipharm.1404-08

Chicago/Turabian Style

AZAM, Mohammed Afzal, and Naga Srinivas TRIPURANENI. 2014. "Selective Phosphodiesterase 4B Inhibitors: A Review" Scientia Pharmaceutica 82, no. 3: 453-482. https://doi.org/10.3797/scipharm.1404-08

Article Metrics

Back to TopTop